Shares in Indian drugmaker Natco Pharma (BSE: 524816) were 13% down on Monday after the company provided an update on the US Food and Drug Administration inspection of its manufacturing facilities.
The regulator has carried out the investigations into sites at Manali, near Chennai, and at Kothur, close to Hyderabad, in the last two months.
Natco Pharma has received Form-483 observations for both facilities, indicating that the investigators may have observed conditions that they deem to be objectionable and which may be in violation of FDA regulations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze